Barclays
IKT icon

Barclays’s Inhibikase Therapeutics IKT Stock Holding History

Barclays’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Sell
19,725
-1,623
-8% -$2.9K ﹤0.01% 4389
2026
Q1 		$35.9K Sell
21,348
-73,447
-77% -$130K ﹤0.01% 4427
2025
Q4 		$194K Buy
94,795
+9,217
+11% +$14.7K ﹤0.01% 4340
2025
Q3 		$139K Sell
85,578
-24,674
-22% -$42.7K ﹤0.01% 4517
2025
Q2 		$215K Buy
110,252
+26,252
+31% +$51.4K ﹤0.01% 4225
2025
Q1 		$184K Hold
84,000
– – ﹤0.01% 4092
2024
Q4 		$273K Buy
+84,000
New +$210K ﹤0.01% 4155
2023
Q3 		– Sell
-11,455
Closed -$41.4K – 4644
2023
Q2 		$41.4K Buy
+11,455
New +$42.7K ﹤0.01% 3914

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's IKT Position: Q2 2026 in Review

Barclays reduced its Inhibikase Therapeutics (IKT) stake by 7.6% in Q2 2026, selling an estimated $2.9K and leaving 19,725 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #4389.

Barclays first reported a position in IKT in Q2 2023 and has held it in 8 quarters since. The position peaked at $273K in Q4 2024. 98 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Barclays held 19,725 shares of Inhibikase Therapeutics worth $40K as of Q2 2026.
  • Barclays sold 1,623 Inhibikase Therapeutics shares in Q2 2026, an estimated $2.9K.
  • Inhibikase Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4389 holding.
  • Barclays first reported a position in Inhibikase Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • Barclays's Inhibikase Therapeutics position peaked at $273K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.